DNA甲基化
肝损伤
CpG站点
基因
单核苷酸多态性
甲基化
生物
人口
基因组
肺结核
药品
利福平
医学
药理学
遗传学
基因表达
基因型
病理
环境卫生
作者
Cong Huai,Yuqi Wei,Mo Li,Xiaoqing Zhang,Hao Wu,Xiaoyan Qiu,Lu Shen,Luan Chen,Wei Zhou,Na Zhang,Guanghui Zhu,Ying Zhang,Zhiruo Zhang,Lin He,Shengying Qin
摘要
Tuberculosis ( TB ) is one of the most prevalent infections. However, anti‐ TB drugs induce adverse liver injury in up to 40% of patients. Studies on candidate genes have suggested that single‐nucleotide polymorphisms account for only a small contribution to the occurrence of anti‐TB drug‐induced liver injury ( ATLI ). In this study, whole‐genome DNA methylation analysis was performed to systematically screen the ATLI ‐associated factors in a 49 vs. 51 case‐control population. Next, 34 identified candidate probes were validated using Mass ARRAY in 296 cases and 288 controls. Our results indicated that 12 CpG sites on seven probes were positively associated with ATLI risk. Furthermore, we applied a CRISPR /Cas9‐mediated methylation modifiable cell model and demonstrated that four CpGs in or near the gene region of AK 2 , SLC 8A2 , and PSTPIP 2 affected the cellular response to rifampicin treatment. This study provides new biomarkers associated with ATLI occurrence.
科研通智能强力驱动
Strongly Powered by AbleSci AI